aDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA bDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA cDepartment of Internal Medicine, ...

aNational Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, ...

Researchers from Eutilex Co. Ltd. have presented preclinical data for the novel V-set and immunoglobulin domain-containing 4 (VSIG4)-specific humanized monoclonal antibody, EU-103, being developed as ...

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors. This is an ASCO Meeting Abstract from ...

Therapeutic effect of a VSIG4-specific mAb EU103 in a preclinical model of patient-derived ascites of ovarian cancer. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

Researchers have discovered a protein, V-set Immunoglobulin-domain-containing 4 or VSIG4, as a new biomarker that may help as a therapeutic target for lupus nephritis (LN, lupus-related kidney disease ...

“We have also made exciting progress in our SNS-102 program, with the functional characterization and identification of novel T-cell receptors that may play a role in VSIG4-mediated immunosuppressio ...

Sensei Biotherapeutics, Inc. today presented preclinical data for SNS-101, a conditionally active VISTA-blocking antibody, as well as characterization of VSIG4, an immune checkpoint targeted by Sensei ...